Ilmarinen Mutual Pension Insurance Co decreased its position in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) by 23.2% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 16,900 shares of the life sciences company’s stock after selling 5,100 shares during the period. Ilmarinen Mutual Pension Insurance Co’s holdings in Illumina were worth $4,625,000 at the end of the most recent reporting period.
A number of other large investors have also added to or reduced their stakes in ILMN. Fiduciary Financial Advisors bought a new stake in Illumina during the second quarter worth about $26,000. MCF Advisors LLC increased its position in shares of Illumina by 172.4% during the 2nd quarter. MCF Advisors LLC now owns 158 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 100 shares during the last quarter. E Fund Management Hong Kong Co. Ltd. bought a new position in shares of Illumina during the 3rd quarter valued at about $31,000. Keating Financial Advisory Services Inc. bought a new position in shares of Illumina during the 2nd quarter valued at about $32,000. Finally, Rakuten Securities Inc. purchased a new position in shares of Illumina during the 2nd quarter valued at about $33,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.
Illumina News Roundup
Investors following ILMN have been watching these news items:
- Positive Sentiment: A proposed Senate bill would clarify Medicaid coverage for whole-genome and whole-exome sequencing for certain children. If enacted, broader coverage could support demand for sequencing, but the proposal remains early-stage. Genomic Answers for Children’s Health Act of 2026
- Neutral Sentiment: Bernstein reportedly maintained a Hold rating, suggesting a cautious stance rather than a new positive catalyst. Illumina Gets a Hold from Bernstein
- Negative Sentiment: Voluntary Class II recalls linked to cybersecurity vulnerabilities in several diagnostic sequencing instruments have heightened concerns about operational risk and data integrity. The report also notes recent weakness in the shares, adding to near-term pressure. Is Illumina Undervalued Following Its Cybersecurity Recalls?
Insider Transactions at Illumina
In other Illumina news, Director Keith A. Meister sold 98,833 shares of the company’s stock in a transaction that occurred on Wednesday, November 11th. The stock was sold at an average price of $216.87, for a total transaction of $21,433,912.71. Following the completion of the transaction, the director owned 208,826 shares of the company’s stock, valued at $45,288,094.62. This represents a 32.12% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Scott D. Ericksen sold 267 shares of the stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $217.76, for a total value of $58,141.92. Following the completion of the sale, the chief accounting officer owned 14,029 shares of the company’s stock, valued at approximately $3,054,955.04. This trade represents a 1.87% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 1,201,292 shares of company stock valued at $270,151,290. 2.90% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In
A number of analysts recently weighed in on ILMN shares. Jefferies Financial Group set a $235.00 target price on Illumina and gave the stock a “hold” rating in a research report on Monday, November 16th. Zacks Research lowered Illumina from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 1st. Stephens cut shares of Illumina from an “overweight” rating to an “equal weight” rating and set a $275.00 price target on the stock. in a research report on Friday, October 23rd. Wall Street Zen lowered shares of Illumina from a “buy” rating to a “hold” rating in a report on Saturday, November 7th. Finally, Stifel Nicolaus upped their price objective on shares of Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Nine equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat, Illumina currently has an average rating of “Hold” and an average target price of $243.72.
Check Out Our Latest Analysis on Illumina
Illumina Price Performance
Shares of Illumina stock opened at $192.82 on Friday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.63 and a quick ratio of 2.05. Illumina, Inc. has a one year low of $112.65 and a one year high of $309.35. The business’s 50 day simple moving average is $248.27 and its two-hundred day simple moving average is $181.05. The stock has a market capitalization of $29.15 billion, a P/E ratio of 33.19, a price-to-earnings-growth ratio of 2.62 and a beta of 1.46.
Illumina (NASDAQ:ILMN – Get Free Report) last issued its earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.36 by $0.26. Illumina had a net margin of 19.72% and a return on equity of 28.38%. The firm had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.15 billion. During the same quarter last year, the business earned $1.34 earnings per share. The business’s revenue was up 4.2% on a year-over-year basis. Analysts forecast that Illumina, Inc. will post 5.43 EPS for the current year.
About Illumina
Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.
Recommended Stories
- Five stocks we like better than Illumina
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
